EGFR and non-small cell lung carcinoma: Other EGFR inhibitors such as afatinib, dacomitinib, lapatinib, neratinib, osimertinib, and vandetanib are used in various cancers such as NSCLC, small cell lung cancer, and breast cancer and target EGFR mutations.